| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Gross Profit | 0 | - |
| Cost Of Revenue | - | - |
| Operating Income | -2.1MM | -12% |
| Operating Expenses | 2.1MM | -12% |
| Net Income | - | - |
| R&D | 829.6K | -25% |
| G&A | 1.3MM | -1% |
| Amortization | 27K | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
COLUMBUS, Ohio, January 27, 2024--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
DUBLIN, Ohio, December 01, 2023--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
DUBLIN, Ohio, October 06, 2023--Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
DUBLIN, Ohio, August 10, 2023--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
“Although the traditional exchange has been a part of Navidea’s history and may be in the future, our strategy and approach remains resolute in the face of change," said a statement.
DUBLIN, Ohio, July 31, 2023--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.
DUBLIN, Ohio, July 29, 2023--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.
DUBLIN, Ohio, July 27, 2023--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
DUBLIN, Ohio, July 13, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company’s Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea’s stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Separately
DUBLIN, Ohio, June 30, 2023--Following the Company’s Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.